Protalix BioTherapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the 3rd quarter of 2026, total revenues were $21.9 million compared to $17.9 million in the 3rd quarter of 2025.
- For the first 9 months of 2026, total revenues were $75.6 million compared to $43.6 million for the first 9 months of 2025, including the previously reported 25 milestone payment.
- Third-quarter revenues from selling goods were $21.8 million compared to $17.7 million in the 3rd quarter of 2025, while first-nine-month revenues from selling goods were $49.1 million compared to $43.1 million for the first 9 months of 2025.
- The increase in revenues from selling goods was driven mainly by higher sales of erfarvirtrikezi.
- Third-quarter cost of revenues was $7.9 million compared to $8.3 million in the same period in 2025; the decrease was mainly attributable to lower sales to FireCruz, partially offset by higher sales to Kierzy and Pfizer.
- R&D expenses were $6.9 million compared to $4.5 million in the prior year period, while SG&A expenses were $3.1 million, up $0.2 million from the prior year period.
- Net income for the quarter was $4 million or $0.05 per share basic and diluted, compared to net income of $2.4 million or $0.03 per share basic and diluted in the 3rd quarter of 2025.
- For the first 9 months, net income was $26.1 million or $0.33 per share basic and $0.31 per share diluted.
- Cash, cash equivalents, and short-term bank deposits totaled $48.5 million as of September 30th, 2026, compared to $40.7 million as of June 30th, 2026; the company had no outstanding debt or warrants.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, ladies and gentlemen, and welcome to the Protalix BioTherapeutics Third Quarter 2026 Financial and Business Results Conference Call. As a reminder, this conference is being recorded. I will now turn the conference over to our host, Mr. Mike Moyer of LifeSci Advisors, Investor Relations for Protalix. Thank you. Please go ahead.
Thank you, operator, and welcome to the Protalix BioTherapeutics Third Quarter 2026 Financial Results and Business Update Conference Call. With me today are Dror Bashan, President and CEO, and Gilad Mamlok, Senior Vice President and Chief Financial Officer. A press release announcing the financial results and corporate updates was issued this morning and is available now on the Protalix website. Please take a moment to read the disclaimer about forward-looking statements in the press release. The earnings in this teleconference include forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially from the statements made. Factors that could cause actual results to differ are described in the disclaimer and in Protalix filings with the U.S. Securities and Exchange Commission. I will now turn the call over to Mr. Bashan.
Dror? Thank you, Mike, and thank you everyone for joining us for this call.
We concluded the first nine months of 2026 with revenues of $75.6 million, reflecting our continued progress and growing financial position, which supports our ability to execute our strategy and advance our key priorities. We end the quarter with cash and deposit of $48.5 million, a position of strength that enables us to continue advancing PRX-115 for uncontrolled gout, as well as our pipeline in rare renal diseases. Gilad will walk through the details of the quarter. Looking ahead, we see Elfabrio as the foundation of our business, with PRX-115 as an important growth opportunity. Elfabrio continues to expand its global reach, with approval in multiple markets outside the U.S.
With the global Fabry market projected to reach approximately $3.2 billion by 2031, we believe Elfabrio is positioned to capture a significant portion, supported by our partnership with Chiesi. Our commercial foundation enable us to advance PRX-115 in uncontrolled gout. Uncontrolled gout is a disease with low quality of life and high unmet need. This represents a blockbuster uricase market opportunity. PRX-115 is a PEGylated uricase designed for high specific activity, prolonged circulation half-life, and reduced immunogenicity. We believe PRX-115 has the potential to be best-in-class therapy. Today, at the American College of Rheumatology, or ACR Convergence 2026, we are presenting individual patient data from our phase I study, 115. The individual patient data reinforce our previous findings and show PRX-115 plasma levels measurable up to 85 days.
Our positive uric lowering data supports the potential for less frequent dosing, which is what our phase II RELEASE study is designed to test. This is a double-blind, placebo-controlled phase II study in uncontrolled gout patients. It tests PRX-115 with a fixed dose across different dosing intervals with and without methotrexate. The RELEASE study is actively enrolling, and we expect top-line results in the second half of next year. Beyond PRX-115, we are building a pipeline in rare renal diseases. We believe our partner commercial business, our balance sheet, and no debt or warrants, and our focused pipeline limit downside risk while preserving significant upside potential as we advance our pipeline. With that, I will turn the call over to Gilad for a detailed review of the financial results and outlook. Gilad, please. Thank you, Dror.
For the third quarter of 2026, total revenues were $21.9 million compared to $17.9 million in the third quarter of 2025. For the first nine months of 2026, total revenues were $75.6 million compared to $43.6 million for the first nine months of 2025, which includes the previously reported $25 million milestone payment received from Chiesi. For the third quarter of 2026, revenues from selling goods were $21.8 million compared to $17.7 million in the third quarter of 2025, an increase of $4.1 million. For the first nine months of 2026, revenues from selling goods were $49.1 million compared to $43.1 million for the first nine months of 2025, an increase of $6 million. The increase was driven mainly by higher sales of Elfabrio to Chiesi.
For the remainder of the results, I will report only on the third quarter, and you can refer to this morning's press release for additional year-to-date data. Cost of revenues was $7.9 million compared to $8.3 million in the same period in 2025, a decrease of $0.4 million. The decrease was mainly attributable to lower sales to Fiocruz, partially offset by higher sales to Chiesi and Pfizer. R&D expenses were $6.9 million compared to $4.5 million in the prior year period, an increase of $2.4 million. The increase was mainly driven by higher subcontractor expenses related to the RELEASE study, partially offset by a $1 million grant recorded under the R&D Law as a reduction of R&D expenses, which we are eligible for, and we intend to file for grants under the R&D Law.
We expect to continue to incur expenses as the RELEASE study progresses and additional preclinical and clinical programs advance. SG&A expenses were $3.1 million, up $0.2 million from prior year period, largely attributable to $0.1 million higher professional fees and $0.1 million higher salary and related expenses. Financial income net was $0.6 million compared to $0.1 million in the third quarter of 2025. The change was mainly due to exchange rate fluctuations and higher interest income. Taxes on income were $0.7 million compared to a tax benefit of $0.1 million in the third quarter of 2025. The tax expense resulted mainly from taxes on income derived from global intangible low-taxed income, or GILTI. Net income for the quarter was $4 million, or $0.05 per share basic and diluted, compared to net income of $2.4 million, or $0.03 per share basic and diluted in the third quarter of 2025.
For the first nine months, net income was $26.1 million, or $0.33 per share basic and $0.31 per share diluted. Turning to the balance sheet, cash equivalents, and short-term bank deposits totaled $48.5 million as of September 30, 2026, compared to $40.7 million as of June 30, 2026. We have no outstanding debt or warrants, providing us with substantial financial flexibility to support our continued pipeline advancement. With that, I will turn the call back over to Dror.
Thank you, Gilad. In closing, I would like to emphasize that we concluded the first nine months of 2026 with revenues of $75.6 million, reflecting the continued progress and growing financial position, which supports our ability to execute our strategy and advance our key priorities. Now, I will ask the operator to open the call for questions.
Thank you. We will now be conducting a question-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question is from Ram Selvaraju from H.C. Wainwright. Please proceed with your question.
Thanks so much for taking our questions, and congratulations on all of this recent progress. Two points. Firstly, I was wondering if you could give us some more granularity on the degree of predictability we might be able to expect with regard to revenue recognition coming from KEVEYIS and sales of Elfabrio, and if the most recent quarterly result indicates a potential new plateau or a new level that we should anticipate being able to use as a sort of a baseline reference. I also wanted to ask about the most recent data that you have showcased with PRX-115 and what the implications of this are on two fronts.
Firstly, the convenience profile of this asset in the treatment refractory gout context and how this might position it as a potential best-in-class or best-in-disease drug within the uricase class, as well as the potential implications of less frequent dosing and more stable levels and overall therapeutic activity sustained after more infrequent dosing from an efficacy standpoint compared to existing currently available uricase drugs.
Thank you. Regarding the first question, Ram, we do see a very nice year from Elfabrio.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
